NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$5.67
-0.01 (-0.18 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.46
Now: $5.67
$5.70
50-Day Range
$4.83
MA: $6.20
$7.38
52-Week Range
$3.07
Now: $5.67
$7.45
Volume905,334 shs
Average Volume1.94 million shs
Market Capitalization$1.70 billion
P/E Ratio13.83
Dividend YieldN/A
Beta1.27
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Amneal Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120
Employees6,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.32 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Market Cap$1.70 billion
Next Earnings Date5/7/2021 (Confirmed)
OptionableOptionable

Headlines

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Short Interest Update
April 15, 2021 |  americanbankingnews.com
Amneal Pharmaceuticals (NYSE:AMRX) Stock Price Down 4.1%
April 8, 2021 |  americanbankingnews.com
A Preview Of Amneal Pharmaceuticals's Earnings
February 25, 2021 |  finance.yahoo.com
Here's what Wall Street expects from Amneal Pharmaceuticals A's earnings
February 24, 2021 |  markets.businessinsider.com
AMRX or PCRX: Which Is the Better Value Stock Right Now?
January 15, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

158th out of 2,018 stocks

Pharmaceutical Preparations Industry

66th out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
$5.67
-0.01 (-0.18 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

Is Amneal Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amneal Pharmaceuticals stock.
View analyst ratings for Amneal Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amneal Pharmaceuticals?

Wall Street analysts have given Amneal Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 3,160,000 shares, a decrease of 43.6% from the March 15th total of 5,600,000 shares. Based on an average trading volume of 2,070,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 3.3% of the company's stock are sold short.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for Amneal Pharmaceuticals
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, May 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its earnings results on Thursday, February, 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.13 by $0.01. The firm had revenue of $510 million for the quarter, compared to analyst estimates of $506.91 million. Amneal Pharmaceuticals had a trailing twelve-month return on equity of 42.02% and a net margin of 3.30%. The company's revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 earnings per share.
View Amneal Pharmaceuticals' earnings history
.

How has Amneal Pharmaceuticals' stock been impacted by Coronavirus?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRX shares have increased by 74.5% and is now trading at $5.67.
View which stocks have been most impacted by COVID-19
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY21 earnings guidance on Friday, February, 26th. The company provided earnings per share guidance of $0.70-0.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.71. The company issued revenue guidance of $2.1-2.2 billion, compared to the consensus revenue estimate of $2.05 billion.

What price target have analysts set for AMRX?

6 brokerages have issued twelve-month target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Amneal Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Chirag K. Patel, Co-Founder, Co-CEO, Pres & Director (Age 54, Pay $22.04k)
  • Mr. Chintu Patel R.Ph., R.Ph, Co-Founder, Co-CEO & Director (Age 49, Pay $29.85k)
  • Mr. Anastasios G. Konidaris, Exec. VP & CFO (Age 54, Pay $856.85k)
  • Ms. Nikita Shah, Exec. VP and Chief HR Officer & Strategic Planning Officer (Age 43, Pay $720.52k)
  • Mr. Joseph Todisco MBA, Exec. VP & Chief Commercial Officer of Specialty (Age 45, Pay $790.12k)
  • Mr. Andrew S. Boyer, Exec. VP & Chief Commercial Officer of Generics (Age 55, Pay $1.15M)
  • Mr. Stephen J. Manzano, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Sanjiv Patel, Sr. VP of Operations
  • Dr. Nikunj Patel, Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
  • Mr. Sanjay Kumar Jain, Pres of India Operations

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include NEXT Financial Group Inc (0.00%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul M Meister, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which major investors are buying Amneal Pharmaceuticals stock?

AMRX stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $5.67.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals has a market capitalization of $1.70 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 6,000 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

Where are Amneal Pharmaceuticals' headquarters?

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.